Carglumic acid

Carglumic acid, sold under the brand name Carbaglu among others, is used for the treatment of hyperammonaemia.^[3][6][7] Carglumic acid is a carbamoyl phosphate synthetase 1 (CPS 1) activator.^[3]

Carglumic acid

Clinical data
Trade names	Carbaglu, Ucedane
Other names	(S)-2-ureidopentanedioic acid
AHFS/Drugs.com	Monograph
License data	US DailyMed: Carglumic acid
Pregnancy category	AU: B1
Routes of administration	By mouth
ATC code	A16AA05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[1] CA: ℞-only[2] US: ℞-only[3] EU: Rx-only[4][5]
Pharmacokinetic data
Bioavailability	30%
Protein binding	Undetermined
Metabolism	Partial
Elimination half-life	4.3 to 9.5 hours
Excretion	Fecal (60%) and kidney (9%, unchanged)
Identifiers
IUPAC name (2S)-2-(carbamoylamino)pentanedioic acid
CAS Number	1188-38-1 N
PubChem CID	121396
IUPHAR/BPS	7458
DrugBank	DB06775 Y
ChemSpider	1265942 N 108351 N
UNII	5L0HB4V1EW
KEGG	D07130 Y
ChEBI	CHEBI:71028 N
ChEMBL	ChEMBL1201780 N
CompTox Dashboard (EPA)	DTXSID7046706
ECHA InfoCard	100.116.323
Chemical and physical data
Formula	C6H10N2O5
Molar mass	190.155 g·mol−1
3D model (JSmol)	Interactive image
SMILES C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N
InChI InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1 Y Key:LCQLHJZYVOQKHU-VKHMYHEASA-N Y
NY (what is this?)  (verify)

The most common adverse effects include vomiting, abdominal pain, pyrexia (fever), and tonsillitis, anemia, diarrhea, ear infection, other infections, nasopharyngitis, decreased hemoglobin levels, and headache.^[3]

It was approved for medical use in the United States in March 2010.^[8] Carglumic acid is an orphan drug.^[9][10] It is available as a generic medication.^[11]

Medical uses

Carglumic acid is indicated for the treatment of acute hyperammonemia and chronic hyperammonemia.^[3][4][5]